Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using ...

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration (FDA ) leaders said on Tuesday they would adopt a new COVID-19 vaccination regulatory ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the ...